Bionano Genomics (BNGO) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

BNGO Stock Forecast


Bionano Genomics stock forecast is as follows: an average price target of $1.00 (represents a 412.82% upside from BNGO’s last price of $0.20) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

BNGO Price Target


The average price target for Bionano Genomics (BNGO) is $1.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $1.00 to $1.00. This represents a potential 412.82% upside from BNGO's last price of $0.20.

BNGO Analyst Ratings


Buy

According to 5 Wall Street analysts, Bionano Genomics's rating consensus is 'Buy'. The analyst rating breakdown for BNGO stock is 0 'Strong Buy' (0.00%), 3 'Buy' (60.00%), 2 'Hold' (40.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Bionano Genomics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 28, 2024Sung Ji NamScotiabank$1.00$0.5195.08%412.82%
May 16, 2024Mark MassaroBTIG$2.00$1.1573.91%925.64%
May 25, 2023Bionano Genomics'sEF Hutton$175.00$65.00169.23%89643.59%
Dec 12, 2022BTIG$350.00$219.0059.82%179387.18%

The latest Bionano Genomics stock forecast, released on Aug 28, 2024 by Sung Ji Nam from Scotiabank, set a price target of $1.00, which represents a 95.08% increase from the stock price at the time of the forecast ($0.51), and a 412.82% increase from BNGO last price ($0.20).

Bionano Genomics Price Target by Period


1M3M12M
# Anlaysts--2
Avg Price Target--$1.50
Last Closing Price$0.20$0.20$0.20
Upside/Downside-100.00%-100.00%669.23%

In the current month, the average price target of Bionano Genomics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Bionano Genomics's last price of $0.20. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Nov 18, 2024BTIGNeutralNeutralHold
Sep 10, 2024BTIGBuyNeutralDowngrade
Aug 28, 2024ScotiabankSector OutperformSector PerformDowngrade
May 16, 2024BTIGBuyBuyHold
May 25, 2023EF HuttonBuyInitialise
Jan 05, 2023ScotiabankSector OutperformInitialise
Jan 25, 2021Odeon Capital Group LLCBuyBuyHold
Jan 16, 2021OppenheimerBuyBuyHold
Dec 30, 2020OppenheimerOutperformOutperformHold

Bionano Genomics's last stock rating was published by BTIG on Nov 18, 2024. The company gave BNGO a "Neutral" rating, the same as its previous rate.

Bionano Genomics Financial Forecast


Bionano Genomics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$9.32M$8.66M$7.42M$8.21M$7.22M$6.67M$5.70M$6.30M$4.66M$3.86M$3.17M$3.99M$2.20M$1.18M$1.14M$2.79M$3.31M
Avg Forecast$10.47M$9.79M$9.03M$8.19M$8.63M$8.06M$7.28M$6.72M$6.30M$7.76M$8.02M$8.48M$10.55M$9.08M$8.29M$7.21M$8.09M$6.79M$6.28M$5.70M$5.57M$4.22M$3.50M$2.97M$3.50M$2.07M$863.00K$1.70M$4.42M$4.03M
High Forecast$13.74M$12.84M$11.85M$10.74M$11.32M$10.57M$9.56M$10.28M$6.50M$10.18M$8.02M$8.48M$10.94M$11.92M$10.88M$9.47M$10.62M$6.79M$6.28M$5.70M$5.57M$4.22M$3.50M$2.97M$3.50M$2.07M$863.00K$1.70M$4.42M$4.03M
Low Forecast$8.70M$8.13M$7.50M$6.80M$7.17M$6.69M$6.05M$4.95M$6.00M$6.44M$8.02M$8.48M$9.94M$7.54M$6.89M$5.99M$6.72M$6.79M$6.28M$5.70M$5.57M$4.22M$3.50M$2.97M$3.50M$2.07M$863.00K$1.70M$4.42M$4.03M
# Analysts22221114312241111111111101010101099
Surprise %-------------1.03%1.04%1.03%1.01%1.06%1.06%1.00%1.13%1.10%1.10%1.07%1.14%1.06%1.37%0.67%0.63%0.82%

Bionano Genomics's average Quarter revenue forecast for Dec 23 based on 4 analysts is $10.55M, with a low forecast of $9.94M, and a high forecast of $10.94M. BNGO's average Quarter revenue forecast represents a 13.25% increase compared to the company's last Quarter revenue of $9.32M (Sep 23).

Bionano Genomics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts22221114312241111111111101010101099
EBITDA-------------$-31.50M$-39.24M$-37.02M$-36.80M$-29.28M$-29.69M$-27.63M$-17.10M$-20.19M$-18.05M$-8.96M$-10.56M$-9.86M$-7.21M$-9.45M$-6.71M$-5.54M
Avg Forecast$-10.47M$-9.79M$-9.03M$-8.19M$-8.63M$-8.06M$-7.28M$-6.72M$-6.30M$-7.76M$-8.02M$-8.48M$-10.55M$-9.08M$-8.29M$-7.21M$-8.09M$-6.79M$-6.28M$-14.09M$-5.57M$-4.22M$-3.50M$-8.96M$-3.50M$-2.07M$-7.21M$-1.70M$-4.42M$-4.03M
High Forecast$-8.70M$-8.13M$-7.50M$-6.80M$-7.17M$-6.69M$-6.05M$-4.95M$-6.00M$-6.44M$-8.02M$-8.48M$-9.94M$-7.54M$-6.89M$-5.99M$-6.72M$-6.79M$-6.28M$-11.27M$-5.57M$-4.22M$-3.50M$-7.16M$-3.50M$-2.07M$-5.77M$-1.70M$-4.42M$-4.03M
Low Forecast$-13.74M$-12.84M$-11.85M$-10.74M$-11.32M$-10.57M$-9.56M$-10.28M$-6.50M$-10.18M$-8.02M$-8.48M$-10.94M$-11.92M$-10.88M$-9.47M$-10.62M$-6.79M$-6.28M$-16.91M$-5.57M$-4.22M$-3.50M$-10.75M$-3.50M$-2.07M$-8.66M$-1.70M$-4.42M$-4.03M
Surprise %-------------3.47%4.73%5.13%4.55%4.31%4.73%1.96%3.07%4.78%5.15%1.00%3.02%4.77%1.00%5.55%1.52%1.37%

undefined analysts predict BNGO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Bionano Genomics's previous annual EBITDA (undefined) of $NaN.

Bionano Genomics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts22221114312241111111111101010101099
Net Income-------------$-112.57M$-38.91M$-37.12M$-38.68M$-31.81M$-32.16M$-29.95M$-34.38M$-20.75M$-18.79M$-9.95M$-11.73M$-10.79M$-8.07M$-10.51M$-7.90M$-6.40M
Avg Forecast$-4.53M$-4.25M$-5.89M$-6.90M$-5.59M$-5.71M$-7.15M$-8.16M$-11.58M$-16.96M$-35.66M$-55.31M$-74.77M$-83.26M$-89.52M$-89.76M$-96.52M$-76.59M$-60.82M$-14.12M$-44.25M$-38.91M$-30.41M$-9.95M$-35.48M$-35.48M$-8.07M$-145.30M$-121.65M$-405.50M
High Forecast$-3.53M$-3.31M$-4.59M$-5.38M$-4.36M$-4.45M$-5.57M$-6.36M$-9.03M$-13.22M$-27.80M$-43.12M$-64.45M$-64.91M$-69.78M$-69.97M$-75.24M$-76.59M$-60.82M$-11.30M$-44.25M$-38.91M$-30.41M$-7.96M$-35.48M$-35.48M$-6.46M$-145.30M$-121.65M$-405.50M
Low Forecast$-6.36M$-5.98M$-8.28M$-9.71M$-7.86M$-8.02M$-10.05M$-11.48M$-16.28M$-23.85M$-50.14M$-77.76M$-86.80M$-117.06M$-125.86M$-126.20M$-135.70M$-76.59M$-60.82M$-16.94M$-44.25M$-38.91M$-30.41M$-11.94M$-35.48M$-35.48M$-9.69M$-145.30M$-121.65M$-405.50M
Surprise %-------------1.35%0.43%0.41%0.40%0.42%0.53%2.12%0.78%0.53%0.62%1.00%0.33%0.30%1.00%0.07%0.06%0.02%

Bionano Genomics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BNGO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Bionano Genomics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts22221114312241111111111101010101099
SG&A-------------$24.90M$26.94M$25.98M$25.32M$21.22M$21.78M$20.28M$19.81M$15.33M$13.83M$9.53M$9.43M$8.66M$5.61M$7.37M$5.86M$4.45M
Avg Forecast$30.81M$28.79M$26.58M$24.09M$25.39M$23.71M$21.43M$19.79M$18.53M$22.82M$23.60M$24.96M$31.05M$26.72M$24.40M$21.23M$23.82M$19.99M$18.49M$16.78M$16.40M$12.42M$10.31M$8.74M$10.29M$6.08M$2.54M$5.01M$13.01M$11.86M
High Forecast$40.43M$37.79M$34.88M$31.62M$33.32M$31.11M$28.13M$30.25M$19.12M$29.95M$23.60M$24.96M$32.18M$35.06M$32.02M$27.86M$31.26M$19.99M$18.49M$16.78M$16.40M$12.42M$10.31M$8.74M$10.29M$6.08M$2.54M$5.01M$13.01M$11.86M
Low Forecast$25.59M$23.91M$22.07M$20.01M$21.09M$19.69M$17.80M$14.57M$17.65M$18.95M$23.59M$24.96M$29.25M$22.19M$20.26M$17.63M$19.78M$19.99M$18.49M$16.78M$16.40M$12.42M$10.31M$8.74M$10.29M$6.08M$2.54M$5.01M$13.01M$11.86M
Surprise %-------------0.93%1.10%1.22%1.06%1.06%1.18%1.21%1.21%1.23%1.34%1.09%0.92%1.42%2.21%1.47%0.45%0.38%

Bionano Genomics's average Quarter SG&A projection for Dec 23 is $31.05M, based on 4 Wall Street analysts, with a range of $29.25M to $32.18M. The forecast indicates a 24.72% rise compared to BNGO last annual SG&A of $24.90M (Sep 23).

Bionano Genomics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts22221114312241111111111101010101099
EPS-------------$-3.22$-1.24$-0.12$-0.13$-0.11$-0.11$-0.11$-0.12$-0.07$-0.07$-0.04$-0.06$-0.08$-0.09$-0.30$-0.23$-0.59
Avg Forecast$-0.05$-0.05$-0.07$-0.08$-0.07$-0.07$-0.08$-0.10$-0.13$-0.20$-0.42$-0.64$-0.87$-0.97$-1.04$-1.05$-1.12$-1.13$-0.90$-0.75$-0.65$-0.58$-0.45$-0.45$-0.53$-0.53$-0.87$-2.15$-1.80$-6.00
High Forecast$-0.04$-0.04$-0.05$-0.06$-0.05$-0.05$-0.06$-0.07$-0.11$-0.15$-0.32$-0.50$-0.75$-0.76$-0.81$-0.81$-0.88$-1.13$-0.90$-0.75$-0.65$-0.58$-0.45$-0.45$-0.53$-0.53$-0.87$-2.15$-1.80$-6.00
Low Forecast$-0.07$-0.07$-0.10$-0.11$-0.09$-0.09$-0.12$-0.13$-0.19$-0.28$-0.58$-0.91$-1.01$-1.36$-1.47$-1.47$-1.58$-1.13$-0.90$-0.75$-0.65$-0.58$-0.45$-0.45$-0.53$-0.53$-0.87$-2.15$-1.80$-6.00
Surprise %-------------3.32%1.19%0.11%0.12%0.10%0.12%0.15%0.18%0.12%0.16%0.09%0.12%0.15%0.10%0.14%0.13%0.10%

According to undefined Wall Street analysts, Bionano Genomics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BNGO previous annual EPS of $NaN (undefined).

Bionano Genomics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
BNGOBionano Genomics$0.21$1.00376.19%Buy
STAASTAAR Surgical Company$25.44$54.58114.54%Buy
BDXBecton, Dickinson and Company$225.64$278.7523.54%Buy
WSTWest Pharmaceutical Services$334.26$393.0017.57%Buy
NVSTEnvista$19.24$20.295.46%Hold
ISRGIntuitive Surgical$545.16$550.671.01%Buy
RMDResMed$242.62$233.50-3.76%Hold

BNGO Forecast FAQ


Is Bionano Genomics a good buy?

Yes, according to 5 Wall Street analysts, Bionano Genomics (BNGO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 60.00% of BNGO's total ratings.

What is BNGO's price target?

Bionano Genomics (BNGO) average price target is $1 with a range of $1 to $1, implying a 412.82% from its last price of $0.195. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Bionano Genomics stock go up soon?

According to Wall Street analysts' prediction for BNGO stock, the company can go up by 412.82% (from the last price of $0.195 to the average price target of $1), up by 412.82% based on the highest stock price target, and up by 412.82% based on the lowest stock price target.

Can Bionano Genomics stock reach $0?

BNGO's average twelve months analyst stock price target of $1 supports the claim that Bionano Genomics can reach $0 in the near future.

What are Bionano Genomics's analysts' financial forecasts?

Bionano Genomics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $30.69M (high $41.74M, low $24.85M), average EBITDA is $-30.694M (high $-24.855M, low $-41.736M), average net income is $-26.605M (high $-20.74M, low $-37.406M), average SG&A $90.32M (high $122.81M, low $73.13M), and average EPS is $-0.31 (high $-0.242, low $-0.436). BNGO's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $37.48M (high $49.18M, low $31.12M), average EBITDA is $-37.479M (high $-31.122M, low $-49.181M), average net income is $-21.566M (high $-16.812M, low $-30.321M), average SG&A $110.28M (high $144.72M, low $91.58M), and average EPS is $-0.251 (high $-0.196, low $-0.353).

Did the BNGO's actual financial results beat the analysts' financial forecasts?

Based on Bionano Genomics's last annual report (Dec 2023), the company's revenue was $36.12M, beating the average analysts forecast of $35.14M by 2.78%. Apple's EBITDA was $-215M, beating the average prediction of $-35.141M by 512.53%. The company's net income was $-232M, missing the average estimation of $-337M by -31.08%. Apple's SG&A was $93.5M, missing the average forecast of $103.4M by -9.58%. Lastly, the company's EPS was $-6.81, beating the average prediction of $-3.928 by 73.36%. In terms of the last quarterly report (Sep 2023), Bionano Genomics's revenue was $9.32M, beating the average analysts' forecast of $9.08M by 2.62%. The company's EBITDA was $-31.5M, beating the average prediction of $-9.08M by 246.90%. Bionano Genomics's net income was $-113M, beating the average estimation of $-83.265M by 35.19%. The company's SG&A was $24.9M, missing the average forecast of $26.72M by -6.82%. Lastly, the company's EPS was $-3.22, beating the average prediction of $-0.97 by 232.08%